
0:00
2:14
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Altri episodi di "Pharmaceutical Executive"



Non perdere nemmeno un episodio di “Pharmaceutical Executive”. Iscriviti all'app gratuita GetPodcast.








